Fms-like tyrosine kinase 3 ligand - Celldex Therapeutics

Drug Profile

Fms-like tyrosine kinase 3 ligand - Celldex Therapeutics

Alternative Names: CDX-301; Flt-3 ligand; Flt3-L; Mobista; rhuFlt3L

Latest Information Update: 11 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Amgen
  • Developer Albert Einstein College of Medicine; Amgen; Celldex Therapeutics Inc; Icahn School of Medicine at Mount Sinai
  • Class Adjuvants; Antineoplastics; Cytokines; Recombinant proteins
  • Mechanism of Action Dendritic cell stimulants; Fms-like tyrosine kinase 3 stimulants; Haematopoiesis stimulants; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-small cell lung cancer
  • Phase I/II B cell lymphoma
  • Discontinued Autoimmune disorders; Infections; Malignant melanoma; Non-Hodgkin's lymphoma; Solid tumours; Stem cell mobilisation

Most Recent Events

  • 11 Jun 2018 Discontinued - Phase-II for Malignant melanoma (Combination therapy, Inoperable/Unresectable, Late-stage disease) in USA (Parenteral)
  • 10 May 2018 Interim efficacy data from a phase II trial in Non-small cell lung cancer released by Celldex Therapeutics
  • 11 Dec 2017 Celldex Therapeutics plans to initiate the phase I FLIGHT trial for Malignant melanoma (Combination therapy, Inoperable/Unresectable, Second-line therapy or greater, Metastatic disease) in Australia (ACTRN12617001621303)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top